BIOCRYST PHARMACEUTICALS, INC. Proceeds from Lines of Credit
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Proceeds from Lines of Credit of $73.07 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2022-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2021-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2020-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2020-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2022 was $73.07M.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2021 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- BIOCRYST PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2019 was $19.48M, a 88.13% increase from fiscal 2018.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $73.07M 10-K · filed 2023-02-27 | ||
| 2022-09-30 | $73.07M 10-Q · filed 2022-11-04 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $19.48M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $19.48M 10-Q · filed 2020-11-06 | $19.48M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $19.48M 10-Q · filed 2020-08-07 | $19.48M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $19.48M 10-Q · filed 2020-05-11 | $19.48M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $10.35M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $10.35M 10-Q · filed 2019-11-08 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $22.66M 10-K · filed 2019-03-14 | ||
| 2016-09-30 | $22.66M 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |